Bristol Myers Squibb appointed AstraZeneca's Cristian Massacesi as its new chief medical officer starting August 1, aiming to leverage his experience in oncology and rare diseases to bolster its pipeline amid looming patent expirations. Massacesi’s tenure at AstraZeneca included prioritizing antibody-drug conjugates, radiopharmaceuticals, and cell therapies. Separately, AstraZeneca announced a $50 billion investment in U.S. manufacturing and R&D to expand its capabilities. These moves highlight AstraZeneca's influence on the biopharma sector and Bristol Myers' strategic hiring to advance clinical execution.